BANK VONTOBEL AG | Market Closed - Swiss Exchange 11:20:00 2024-05-30 EDT | ||
| 97.7 USD | +0.21% |
|
| Current month | -1.21% | ||
| 1 month | -1.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 97.7 | +0.21% |
| 24-05-29 | 97.5 | -1.61% |
| 24-05-28 | 99.1 | -0.70% |
| 24-05-24 | 99.8 | -0.20% |
| 24-05-23 | 100 | -0.30% |
Delayed Quote Swiss Exchange
Last update May 30, 2024 at 11:20 am
More quotesStatic data
| Product type | Aktienanleihen |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| RMAS7V | |
| ISIN | CH1315861554 |
| Date issued | 2024-03-01 |
| Strike | 50.89 $ |
| Maturity | 2025-09-02 (460 Days) |
| Parity | 0.05 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | Beides |
| Currency | USD |
Technical Indicators
| Highest since issue | 101 $ |
|---|---|
| Lowest since issue | 97 $ |
| Spread | 8 $ |
| Spread % | 0.81% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.18
USD
Average target price
53.19
USD
Spread / Average Target
+32.37%
- Stock Market
- Certificates
- RMAS7V Certificat
